SCHEMBL4580008

SCHEMBL4580008

Cn1cc(-c2ccc(C#N)c(NCC3CCCO3)c2)c2c1C(=O)CC(C)(C)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.42
HPGD P15428 7/20 0.42
MAPK1 P28482 2/20 0.42
HSD17B10 Q99714 3/20 0.42
TSHR P16473 1/20 0.42
GAA P10253 7/20 0.39
KDM4E B2RXH2 9/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
LMNA P02545 1/20 0.37
USP2 O75604 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
EGLN2 Q96KS0 1/20 0.35
GLA P06280 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
HIF1A Q16665 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4582234 0.85 HSP90AA1 (0.45) ALDH1A1HPGDMAPK1HSD17B10TSHR
SCHEMBL4581631 0.79 HSP90AA1 (0.39) CYP11B2
SCHEMBL4579779 0.75 KDM1A (0.41) ALDH1A1KDM4ECYP11B2
SCHEMBL4432477 0.68 ALDH1A1 (0.63) ALDH1A1HPGDMAPK1HSD17B10TSHR
SCHEMBL7554920 0.65 KDM4E (0.54) ALDH1A1HPGDMAPK1HSD17B10TSHR
SCHEMBL4580721 0.64 HSP90AA1 (0.49) CYP11B2
SCHEMBL23852691 0.60 KDM4E (0.49) ALDH1A1HPGDMAPK1HSD17B10TSHR
SCHEMBL22023254 0.60 CHEK1 (0.50) ALDH1A1HPGDMAPK1HSD17B10GAA
SCHEMBL29596618 0.60 CHEK1 (0.50) ALDH1A1HPGDMAPK1HSD17B10GAA
SCHEMBL22079965 0.60 CHEK1 (0.53) ALDH1A1GAAKDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US claimed
WO-2008024978-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO claimed
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US disclosed
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US disclosed
WO-2008024978-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO disclosed
WO-2008024978-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives MKI67, CCNB1, RB1 ALDH1A1 440/4885HPGD 654/4885MAPK1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.